THE BUDGET IMPACT OF TREATING PATIENTS WITH NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN (PNP) WITH CAPSAICIN 8% PATCH FOR EITHER PREGABALIN-NAIVE OR PREGABALIN-TREATED PATIENTS IN SCOTLAND
Author(s)
Patel S1, Chambers C2, Garnham A2
1Astellas UK, Chertsey, UK, 2Astellas Pharma EMEA, Chertsey, UK
OBJECTIVES: Current practice guidelines in Scotland recommend pregabalin in primary care if first- and second-line treatments (amitriptyline or gabapentin) are ineffective or poorly tolerated. Capsaicin 8% patch (QUTENZA™) is currently used as an add-on to pregabalin and only within a specialist setting. Scottish prescribers have made two suggestions to improve current care; first, using capsaicin 8% patch instead of pregabalin following failure of initial treatments; and second, administering capsaicin 8% patch within primary care. We built a model to evaluate the potential budget impact from implementing the suggested treatment practices METHODS: The model assessed a hypothetical cohort of 100 patients with non-diabetic PNP, treated by a primary care physician, a pain specialist or both (integrated care). Two patient cohorts were modelled: pregabalin-naïve (i.e. previously untreated with) or pregabalin-treated. Costs were estimated for the base-case scenarios (secondary care use of pregabalin only for pregabalin-naïve and -treated patients) and new treatment pathways (replacing pregabalin with capsaicin 8% patch). Model input values included 150mg daily dose of pregabalin and capsaicin 8% patches (1.45 patches/patient; 5.25 months retreatment time). RESULTS: In the base-case scenario for pregabalin-naïve patients, the estimated cost (per 100 patients) was £82,800. The estimated costs of introducing capsaicin 8% patch were £ (£9886 difference) in secondary care, £86,743 (£3943) in primary care and £89,343 (£6543) in integrated care. In pregabalin-treated patients, the estimated base-case scenario cost was £185,200. The estimated costs of introducing capsaicin 8% patch were £175,486 (–£9714 difference) in secondary care, £169,543 (–£15,657) in primary care and £172,143 (–£13,057) in integrated care
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PSY20
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Systemic Disorders/Conditions